We have not addressed other promising biomarkers such as alpha-synuclein radiotracers-like compounds (18F) BF227 and (18F) WC-58 [37,38] because they have not been adequately investigated in DLB patients at the prodromal stage. This evidence concerns the gene SNCA and Lewy body dementia.